Holen Sie sich die Stockscreener-App
2.06
4.63%
-0.10
Handel nachbörslich:
2.06
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Aytu BioPharma Market Sentiment - Benzinga España
Aytu Biopharma Inc (AYTU) Cash Flow - TradingKey
Aytu Biopharma Inc (AYTU) Balance Sheet - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.160| - TradingKey
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aytu Biopharma Inc (AYTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Aytu BioPharma, Inc. Revenue Breakdown – NASDAQ:AYTU - TradingView
Aytu Biopharma Inc (AYTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsGap Fill Strategy - dars.gov.et
AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic ReviewEarnings Beat Streak - dars.gov.et
Aytu BioPharma Holds Steady Near $2.16 Amid Modest Gains – Key Levels in FocusFactor Valuation - DonanımHaber
Aytu BioPharma | SCHEDULE 13G/A: Others - Moomoo
Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
Aytu BioPharma, Inc. Actuals & Estimates (NASDAQ:AYTU) - TradingView
AYTU Forecast — Price Target — Prediction for 2027 - TradingView
Aytu BioPharma, Inc. Actuals & Estimates (LSE:0A8M) - TradingView
0A8M Forecast — Price Target — Prediction for 2027 - TradingView
Aytu Biopharmato Continue Selling Existing - Moomoo
Aytu BioPharma Ends Metadate CD License With Lannett; Sell-Through Allowed After Mutual Termination - TradingView
Aytu BioPharma (AYTU) ends Metadate CD license agreement with Lannett - Stock Titan
Price to sales forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to EBIT forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to revenue forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
AYTU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aytu Biopharma Inc (AYTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aytu Biopharma Inc (AYTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Institutional Confidence - TradingKey
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AYTU: EXXUA's unique profile and RxConnect network drive strong early growth and market resilience - TradingView
AYTU: EXXUA’s unique profile and RxConnect network drive growth and resilience amid market shifts - TradingView
Aytu BioPharma (AYTU) Surges 4.2% as Shares Approach Resistance at $2.28Shakeout Pattern - newsline.com
Aytu BioPharma Inc. (AYTU) Gains 4.23% as Shares Test Key Resistance at $2.28PCR Spike - newsline.com
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aytu BioPharma (AYTU) Slips 1.83% as Stock Tests Key Support Near $2.04WMA Signal - newsline.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AYTU Maintained by Ascendiant Capital -- Price Target Raised to $14.50 - GuruFocus
AYTU Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterUpward Estimate Revision - newsline.com
Aytu BioPharma Gains 5.89% as Small-Cap Biotech Finds TractionDaily Profile - newsline.com
Aytu BioPharma Inc. (AYTU) Gains 3.3% as Shares Approach Resistance at $2.30Channel Breakout - newsline.com
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 - Hastings Tribune
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance ZoneSector ETF Flow - The Legal Advocate
AYTUAytu BioPharma Inc Stock Price and Quote - Finviz
AYTU Q1 2026 Earnings: Narrow EPS Miss Amid Limited Revenue Disclosure; Shares Edge HigherNet Income Trends - newsline.com
AYTU Q1 2026 Earnings: EPS Misses Estimates by 1.88%, Stock Declines Amid Sparse DisclosureReturn On Assets - The Legal Advocate
AYTU: EXXUA’s launch drives growth as legacy ADHD revenues decline, with strong financial footing - TradingView
AYTU Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesEarnings Trend Analysis - The Legal Advocate
AYTU Q1 2026 Earnings EPS Misses Estimates Amidst Operational ChallengesThe Legal Advocate - The Legal Advocate
Aytu BioPharma (AYTU) Holds Near Support Amid Low-Volume TradingWeak Sell Signals - newsline.com
Aytu BioPharma Rallies as Shares Test Key Resistance LevelsCumulative Volume - The Legal Advocate
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):